Clinical Trial Update: Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C

View source ↗

Summary

This Clinical Trials Update describes an Expanded Access Program for Sofosbuvir with ribavirin, with or without pegylated interferon, to treat aggressive post-t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Pegylated interferon alfa-2a (Peginterferon alfa-2a)
• Ribavirin (ribavirin)
• Sofosbuvir (Sovaldi) (sofosbuvir)

Snippet

Sponsor: Gilead Sciences | Conditions: Post-transplant Hepatitis C | Status: APPROVED_FOR_MARKETING